The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Agios Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $20.75 Mil. Agios Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $13.35 Mil.
Hence, Agios Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.55.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Agios Pharmaceuticals Receivables Turnover Related Terms
Agios Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGIO vs ABCL, KOD, IMNM: Receivables Turnover Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (AGIO) has a Receivables Turnover of 1.55 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #247 out of 840 companies in the Biotechnology industry, placing it in the top 29.4%.
Is Agios Pharmaceuticals' Receivables Turnover too high?
Agios Pharmaceuticals' current Receivables Turnover is 1.55. The Biotechnology industry median Receivables Turnover is 5.30. Agios Pharmaceuticals' value of 1.55 is 70.8% below this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #247 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Receivables Turnover compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #247 out of 840 companies for Receivables Turnover. This puts Agios Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.30. Agios Pharmaceuticals' value of 1.55 is 70.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current Receivables Turnover of 1.55 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current Receivables Turnover is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (AGIO) is currently considered Possible Value Trap. The stock's GF Value™ is $84.50, compared to a current price of $41.23 — trading 51.2% below its estimated fair value. The current Receivables Turnover is 1.55 and 70.8% below the Biotechnology industry median of 5.30. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Agios Pharmaceuticals (AGIO), the current Receivables Turnover is 1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 51.2% below its estimated GF Value™ of $84.50.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for AGIO:
Receivables Turnover: 1.55
GF Value™: $84.50 vs. price of $41.23 (51.2% below fair value)
Industry Position: 70.8% below the Biotechnology median (#247 of 840)
No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for AGIO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGIO has been successfully added to your 
